AK1820

Asahi Kasei Pharma Corporation · Phase 3 active Small molecule

AK1820 is an investigational therapeutic targeting immune or inflammatory pathways, though its precise mechanism remains proprietary.

At a glance

Generic name	AK1820
Sponsor	Asahi Kasei Pharma Corporation
Modality	Small molecule
Phase	Phase 3

Mechanism of action

As a Phase 3 asset from Asahi Kasei Pharma, AK1820 is under clinical development for an undisclosed indication. Without public disclosure of its molecular target or mechanism of action, the exact pathway it modulates cannot be confirmed from available sources.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AK1820 CI brief — competitive landscape report
AK1820 updates RSS · CI watch RSS
Asahi Kasei Pharma Corporation portfolio CI